View Cart  

Despite Lilly’s Phase III Alzheimer’s Stumbles, Analysts Hope for Filing

Eli Lilly’s Alzheimer’s disease candidate solanezumab failed to meet its primary endpoints in a pair of closely watched Phase III trials, but flickers of promise seen in mildly affected Alzheimer’s patients have lifted some analysts’ hopes the drug could still be filed for regulatory approval.

To View This Article:


Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $25.00